CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Non Small Cell Lung Cancer|Triple Negative Breast Cancer|Melanoma|Head and Neck Cancer
Interventions: BIOLOGICAL: CAB-ROR2-ADC|BIOLOGICAL: PD-1 inhibitor
Sponsor: BioAtla, Inc.